News
First Patients Enrolled in IMPRoVED-AF Study Evaluating vMap in Persistent and Recurrent AF
Vektor Medical today announced that the first patients have been enrolled in the IMPRoVED-AF clinical study. The prospective, randomized, controlled, multi-center trial is designed to evaluate the clinical benefit of using vMap®, the company’s FDA-cleared, non-invasive arrhythmia analysis technology, to guide ablation strategies beyond pulmonary vein isolation (PVI) in patients with persistent and recurrent atrial fibrillation (AF).
The first patients were enrolled at Baptist Health Lexington, a leader in cardiac care and innovation.
“Enrolling the first patient in the IMPRoVED-AF study marks an important milestone in our ongoing efforts at Baptist Health to further advance care for our patients suffering from cardiac arrhythmias,” said Dr. Gery Tomassoni, Principal Investigator and cardiac electrophysiologist at Baptist Health Lexington. “Using vMap to determine a targeted ablation strategy beyond the pulmonary veins provides an opportunity to address arrhythmia sources that were previously undetectable.”
The IMPRoVED-AF study will enroll up to 384 patients across approximately 20 centers in the U.S. and Europe. All patients receive a standard 12-lead ECG; those randomized to the intervention arm will receive additional driver ablation based on vMap’s analysis. The study's primary endpoint is freedom from AF at 12 months, with or without antiarrhythmic drugs.
Vektor’s vMap™ Technology Used Alongside SAbR Planning Software (Varian, Palo Alto, CA) for Non-Invasive Mapping and Radio-ablation of Refractory Ventricular Tachycardia
Life-threatening heart rhythm disorders such as ventricular tachycardia may be eliminated using cutting-edge, non-invasive technology as an alternative to standard invasive catheter ablation procedures, in some cases. In an abstract and associated poster published at the American College of Physicians’ Southern Regional Conference, researchers report successful use of vMap™ technology to guide stereotactic radiotherapy to destroy diseased heart tissue. Researchers report that this non-invasive mapping and ablation has “shown tremendous promise in recent years.” Importantly, for this patient, his “shock burden decreased from 34 ICD shocks in the 6 months preceding … therapy to 0 ICD shocks in the 11 months after treatment. His quality of life improved significantly, and he has resumed an active lifestyle”.
Vektor Medical, Inc. Chosen as a San Diego Venture Group 2020 Cool Company
Vektor has been selected as one of San Diego Venture Group’s ‘Cool Companies’ for 2020. Connect w/ San Diego Venture Group (SDVG) promotes the formation, funding, and development of innovative new ventures in the San Diego community. "We help innovative companies thrive so they can make a meaningful impact on the economic development of the region, and together create a world-class tech ecosystem," Mike Krenn, CEO of Connect. SDVG’s Cool Companies list highlights the fastest-growing, most exciting startups in Southern California.
Computer-Based 12-Lead ECG Analysis Accurately Maps Ventricular Locations
Researchers, in an abstract and associated poster published in the Heart Rhythm Society’s journal Heart Rhythm, find that computer-based analysis of 12-lead ECG accurately mapped 93% of known ventricular locations to the exact ventricular segment. The computer-based analysis required only 3 minutes, plus or minus 2 minutes, per ECG.
Vektor Medical, Inc. Announces the Closing of Its Series Seed Funding Round to Support the Development and U.S. FDA Clearance of vMap™
Vektor Medical, Inc. is pleased to announce its Series Seed financing round is fully subscribed, and the round is officially closed. The investment round will enable Vektor to further invest in investigative research, efforts toward U.S. Food and Drug Administration 510(K) clearance, and development of a commercial product. “With the support of our investors, we are delighted to have successfully closed this funding round in less than two months and with more investor interest than we had room for in the round.” Rob Krummen, COO and General Counsel
12-Lead ECG-Based Mapping Guides Non-Invasive Radiation Therapy
In an abstract published in the American Heart Association’s journal, Circulation, researchers conclude that a case of stereotactic radioablation of ventricular tachycardia illustrates efficacy of non-invasive 12-lead ECG mapping and radioablation in a patient who failed prior invasive VT therapies.
Computerized Mapping Enables New Procedure for Ventricular Fibrillation
A new procedure developed at UC San Diego Health uses targeted ablation to enable treatment for ventricular fibrillation. The procedure is enabled by the use of electrocardiograms to make a computerized map of the heart’s own voltage.
Vektor Medical, Inc. Successfully Closes Its Convertible Note Funding Round
Today, Vektor Medical, Inc. announces the closing of its Convertible Note funding round. The funds will be used to support research relating to and development of a non-invasive computational arrhythmia mapping device. “We’re excited to welcome our investors on board and join Vektor’s journey in creating the next generation of arrhythmia mapping technology. This funding round enables us to build out our team and further research and develop the technology created by our UCSD founders”. Mike Monko, CEO & Co-Founder of Vektor Medical, Inc.